The FDA announced Wednesday that bebtelovicimab, Eli Lilly’s COVID-19 drug, is no longer authorized to treat COVID-19 due to the development of two new subvariants opposed to those the drug does work.
The Centers for Disease Control and Prevention last week released new estimates that the combined proportion of Covid-19 cases across the Omicron subvariants BQ. 1 and BQ. 1. 1 is over 57% nationally, and already exceeds 50% in all but one individual regions.
The U. S. government The U. S. Food and Drug Administration recommends that all bebtelovimab materials be retained in states for treatment-sensitive variants, which are still circulating with a lower, more prevalent prevalence in the future.
Lilly said in a statement that the company and the FDA
agrees that it is not medically appropriate, at this time, to treat high-risk patients with mild to moderate COVID-19 with bebtelavima in the United States. Based on pseudovirus data, Lilly can verify that bebtelovimbab does not retain neutralizing activity opposite to BQ. 1 and BQ. 1. 1 variants, probably due to substitution of the amino acid K444T. Lilly will suspend all distribution of bebtelavimab. Any unused bebetelovisab would possibly be stored during rest.
But bebtelavima is not the first remedy for covid-19 to lose its effectiveness due to the new variants. Last January, two monoclonal antibody combinations from Eli Lilly and Regeneron halted their approvals and shipments because HHS said they were “highly unlikely” to work. opposed to Omicron.
And unlike Lilly’s former bamlanivimab mAb, whose EUA was revoked in April 2021, the FDA chose to review, rather than repeal, those 3 EUA mAbs.
COVID-19 treatments available in the U. S. The U. S. comes with Pfizer’s Paxlovid, Merck’s Lagevrio and Gilead’s Veklury.
From the beginning, Neogene executives had ambitious goals in the brain when they tested a mobile treatment that could only fight fake tumors.
Its founders helped refine a new technique that would integrate multiple neoantigen targets to create a personalized TCR treatment that would not only deliver blood to fake tumors, but do so sustainably. And they managed to get to the clinic quickly, revealing their first phase I complex tumor program last May.
Unlock this article and others by subscribing to one of our paid plans.
Researchers still have key questions about Eisai’s investigational Alzheimer’s drug, lecanemab, after more phase III knowledge was published in the New England Journal of Medicine Tuesday night.
In the paper, which was published alongside presentations at an Alzheimer’s conference, the trial researchers write that a definition of clinical significance “has not been established. “It has left experts calling for more: the status quo of a prospective confrontation to exactly outline the extent of the difference the drug makes in patients’ lives.
Unlock this article and others by subscribing to one of our paid plans.
Argenx’s Vyvgart is subject to immediate FDA review, thanks to a $102 million Priority Review Voucher (PRV).
The Netherlands-based biotech has recovered bluebird bio’s GRP, the corporations announced Wednesday. PRVs shorten a drug’s review period through the FDA from 10 months to 6 months, although they are sold on the open market for about $100 million each.
Argenx plans to use the explicit price of efgartigimod, its neonatal Fc receptor blocker (FcRn) advertised as Vyvgart for adults with generalized myasthenia gravis (gMG). While Vyvgart received its first approval last December for chronic neuromuscular disease, which is characterized through difficulties with facial expression, speech, swallowing and breathing, CEO Tim Van Hauwermeiren said in a press release that he plans to “be active on fifteen disease targets through 2025. “
Pharmaceutical advertisers on Twitter are over, at least for now. Ad spending among previous big spenders fell last week, according to the most recent knowledge of ad tracker Pathmatics, amid continued turbulence after billionaire boss Elon Musk took over a month ago.
Of the 18 most sensible advertisers tracked by Endpoints News, only two spend: GSK and Bayer. GSK’s spending for the entire week to Sunday’s low was just under $1900. Meanwhile, German drugmaker Bayer remains the industry’s outlier, expanding spending to $499,000 last week from $480,000 the week before. Bayer’s spending also marks a sharp buildup from a month ago and before Musk’s purchase, when he was spending $16,000 a week.
Unlock this article and others by subscribing to one of our paid plans.
After 24 years without confirmation of clinical benefit, the FDA announced Tuesday morning that Viatris (formed through Pfizer’s Mylan and Upjohn) made the decision to recall a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said it was not imaginable to conduct a confirmatory study.
Sulfamylon first won accelerated FDA approval in 1998 as a topical treatment for burns, and the FDA noted that last December, Mylan told the company it was not completing the trial.
Unlock this story right away and sign up to have more than 153,800 biotech professionals read endpoints daily, and it’s free.
The Drugs for Neglected Diseases (DNDi) initiative and Sanofi reported today that their potential sleeping sickness remedy has achieved success rates of up to 95 percent in a Phase II/III study investigating the protection and efficacy of a single dose of acoziborole.
The potentially transformative remedy for sleeping sickness would primarily target African countries, according to information published today in the medical journal The Lancet Infectious Diseases. The clinical trial was conducted through DNDi and partners in the Democratic Republic of Congo (DRC) and Guinea, with the authors noting:
Lexicon Pharmaceutical is not giving up its candidate for type I diabetes, despite repeated FDA denials. This week, the company made its case for a hearing on sotagliflozin in reaction to the FDA’s latest refusal.
The challenge dates back to March 2019, when the FDA made it clear to Lexicon and his now-deceased wife Sanofi that it would approve their application for a potential type I diabetes drug because it didn’t seem safe.
BioNTech strengthens its thin line of small molecules by adding weight to a clinically challenging facet of R
The agreement is divided into two parts: First, BioNTech obtains an exclusive international license to expand and commercialize Ryvu Therapeutics’ STING agonist portfolio as small molecules or in a mixture with other agents.
Unlock this story right away and sign up to have more than 153,800 biotech professionals read endpoints daily, and it’s free.
Amgen, Janssen de J.
Horizon showed “very early discussions” with those corporations related to a potential takeover bid after the Wall Street Journal reported on interest in an acquisition.
Although the company, which has a market capitalization of nearly $18 billion, under pressure that “there can be no certainty that an offering will be made for the company,” HZNP shares rose 31% in after-hours trading to nearly $103. Taking him to the point where he the year.
Unlock this story right away and sign up to have more than 153,800 biotech professionals read endpoints daily, and it’s free.
© Endpoints Company 2022
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.